HomeCompareUSAM vs PFE

USAM vs PFE: Dividend Comparison 2026

USAM yields 20000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 USAM wins by $52481917574412746752.00M in total portfolio value
10 years
USAM
USAM
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full USAM calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — USAM vs PFE

📍 USAM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUSAMPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, USAM + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
USAM pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

USAM
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, USAM beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of USAM + PFE for your $10,000?

USAM: 50%PFE: 50%
100% PFE50/50100% USAM
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

USAM
No analyst data
Altman Z
-6.7
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

USAM buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUSAMPFE
Forward yield20000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$52481917574412746752.00M$49.6K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00$26,258.71
Total dividends collected$52448189483771600896.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: USAM vs PFE ($10,000, DRIP)

YearUSAM PortfolioUSAM Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$2,010,700$2,000,000.00$9,153$693.39+$2.00MUSAM
2$377,983,225$375,831,775.70$8,593$849.25+$377.97MUSAM
3$66,433,479,469$66,029,037,418.28$8,336$1,066.78+$66433.47MUSAM
4$10,916,985,471,987$10,845,901,648,955.73$8,437$1,384.80+$10916985.46MUSAM
5$1,677,384,363,769,318$1,665,703,189,314,291.80$9,013$1,875.40+$1677384363.76MUSAM
6$240,985,175,079,139,100$239,190,373,809,905,920.00$10,306$2,680.72+$240985175079.13MUSAM
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$12,820$4,101.38+$32373573631143.68MUSAM
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$17,673$6,826.70+$4066766648320630.00MUSAM
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$27,543$12,591.86+$477730483406513344.00MUSAM
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$49,560$26,258.71+$52481917574412746752.00MUSAM

USAM vs PFE: Complete Analysis 2026

USAMStock

U.S. Automotive Manufacturing, Inc. manufactures new and rebuilt automotive friction products. The company's line of friction automotive products include brake lining, integrally molded and riveted brake pads, and remanufactured brake shoes. Brake pads, brake shoes or a combination of both are incorporated in all makes and models of American and imported automobiles. It markets various grades of friction lining, asbestos, non-asbestos organic, and semi-metallic formulas, suitable for use by the automotive and light truck after-markets. It generally produces the replacement brakes under the same process used to manufacture the vehicle's original equipment. The company sells its products to wholesale and retail automotive distributors, mass merchandisers, chain stores, and to other brake manufacturers in the United States and in 11 foreign countries. U.S. Automotive Manufacturing, Inc. was founded in 1992 and is based in Sanford, Florida.

Full USAM Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this USAM vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

USAM vs SCHDUSAM vs JEPIUSAM vs OUSAM vs KOUSAM vs MAINUSAM vs JNJUSAM vs MRKUSAM vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.